Abeona Therapeutics Inc. Common StockABEO
Scheduled
Abeona Therapeutics Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Abeona Therapeutics has transitioned to a commercial-stage company following the approval and late-last-year launch of ZivaScan for recessive dystrophic epidermolysis bullosa.
- ZivaScan generated $11.4 million in net product revenue, representing 31% quarter-over-quarter growth and the third consecutive quarter of revenue increases since launch.
- The company had onboarded seven qualified treatment centers, covering about 40% of the addressable market in states where those centers are located, and had commercially treated 12 patients as of August 13.
- Abeona reported more than 95% commercial coverage for ZivaScan, Medicaid coverage in all 50 states, and no ultimate insurance denials to date.
- Abeona had $146 million in cash to fund its commercial launch and ABO701 I&D work.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring